Business
Omnicell Unveils Innovative IVX Station Robotic Compounding Technology in Winter 2022 Release
New Technology and Enhancements to Intelligent Infrastructure Designed to Support Safer, Smarter Pharmacy Care MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--
About this update from Omnicell, Inc.
[{"type":"text","content":"\nNew Technology and Enhancements to Intelligent Infrastructure Designed to Support Safer, Smarter Pharmacy Care\n\n MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--\nOmnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced the launch of IVX Station. This innovative solution is designed to scale the benefits of leveraging IV robotic technology, making it accessible to the mainstream market.\n\nOmnicell’s Winter 2022 Release introduces new technology and enhancements to existing solutions that are expected to add value for customers. The new solutions and capabilities are intended to automate workflows, optimize operations and, most importantly, help improve patient care in an increasingly complex regulatory environment.\n\nIVX Station: Reimagining Technology for Maximum Throughput and Reliability\n\nAccording to the Institute for Safe Medication Practices (ISMP),1 not only are manual sterile compounding practices labor intensive, but they also can create patient safety risks. IV robotics have demonstrated proven benefits for safe, efficient sterile compounding for over 15 years, yet adoption of the technology has been limited due to throughput and reliability concerns.2,3\n\nOmnicell’s completely reimagined, fully automated IV compounding robot is designed to deliver the patient safety, accuracy, cost savings, supply chain control, and compliance benefits of its predecessors while addressing industry issues with throughput and reliability. IVX Station supports three times the throughput speed of current IV robotic technology,4 features a design focused on high reliability with a precision-machined super structure to eliminate the number one cause of downtime – re-calibration, and maintains the approximate footprint of a four-foot hood.\n\nIVX Station is available through Omnicell’s IV Compounding Service, which combines the technology with expertly trained pharmacy technicians and services in an effort to ensure value realization. This “as-a-Service” approach should help to reduce reliance on outsourced sterile compounding, while allowing health systems to reduce drug waste in the operating room.\n\n“Nearly a decade ago, University of Rochester Medical Center began a journey toward a fully autonomous approach to medication management as an early ado...